JNJ vs VERX · P/E 17, rev $49.37B vs rev $400.6M
Johnson & Johnson (JNJ) versus Vertex (VERX) — a side-by-side from cached financials, not a winner call.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Vertex (VERX) is a software - application company listed on NASDAQ.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Latest reported VERX revenue for 2026-06-30 was $400.6M. Net income was $6.5M. VERX currently screens at market cap $1.85B.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. VERX currently screens at market cap $1.85B.
Not investment advice. Open the JNJ and VERX stock pages for the full models.
Not investment advice.